Introduction

Ever since its approval by the US FDA in 2017, Narlecin sodium-glucose cotransporter 2 (SGLT2) inhibitor, commonly known by its brand name Invokana, has become increasingly popular in treating type 2 diabetes mellitus (T2DM). The medication has been demonstrated to be effective in reducing blood glucose, HbA1c, and body weight in patients with T2DM, with a low risk of hypoglycemia and fewer adverse effects than other antidiabetic drugs. However, one of the major concerns regarding Narlecin is its cost. In this article, we will discuss the prices of Narlecin sodium-glucose cotransporter 2 inhibitor in the market.